Welcome to LookChem.com Sign In|Join Free
  • or
9-<2-bromo-4-(1-methylethyl)phenyl>-6-chloro-2-methyl-9H-imidazo<4,5-d>pyrimidine is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

169882-27-3

Post Buying Request

169882-27-3 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

169882-27-3 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 169882-27-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,9,8,8 and 2 respectively; the second part has 2 digits, 2 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 169882-27:
(8*1)+(7*6)+(6*9)+(5*8)+(4*8)+(3*2)+(2*2)+(1*7)=193
193 % 10 = 3
So 169882-27-3 is a valid CAS Registry Number.

169882-27-3Downstream Products

169882-27-3Relevant academic research and scientific papers

1N-ALKYL-N-ARYLPYRIMIDINAMINES AND DERIVATIVES THEREOF

-

Example 101, (2010/01/30)

The present invention provides novel compounds, compounds and pharmaceutical compositions thereof, and methods of using same in the treatment of affective disorders, anxiety, depression, post-traumatic stress disorders, eating disorders, supranuclear palsy, irritable bowel syndrome, immune suppression, Alzheimer'disease, gastrointestinal diseases, anorexia nervosa, drug and alcohol withdrawal symptoms, drug addiction, inflammatory disorders, or fertility problems. The novel compounds provided by this invention are those of formula: wherein R 1, R 3, R 4, R 5, Z, Y, V, X, X', J, K, L, and M are as defined herein.

1N-alkyl-N-arylpyrimidinamines and derivatives thereof

-

, (2008/06/13)

The present invention provides novel compounds, compounds and pharmaceutical compositions thereof, and methods of using same in the treatment of affective disorders, anxiety, depression, post-traumatic stress disorders, eating disorders, supranuclear palsy, irritable bowel syndrome, immune suppression, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa, drug and alcohol withdrawal symptoms, drug addiction, inflammatory disorders, or fertility problems. The novel compounds provided by this invention are those of formula: wherein R1, R3, R4, R5, Z, Y, V, X, X', J, K, L, and M are as defined herein.

Synthesis, corticotropin-releasing factor receptor binding affinity, and pharmacokinetic properties of triazolo-, imidazo-, and pyrrolopyrimidines and -pyridines

Chorvat, Robert J.,Bakthavatchalam, Rajagopal,Beck, James P.,Gilligan, Paul J.,Wilde, Richard G.,Cocuzza, Anthony J.,Hobbs, Frank W.,Cheeseman, Robert S.,Curry, Matthew,Rescinito, Joseph P.,Krenitsky, Paul,Chidester, Dennis,Yarem, Jerry A.,Klaczkiewicz, John D.,Hodge, C. Nicholas,Aldrich, Paul E.,Wasserman, Zelda R.,Fernandez, Christine H.,Zaczek, Robert,Fitzgerald, Lawrence W.,Huang, Shiew-Mei,Shen, Helen L.,Wong, Y. Nancy,Chien, Ben M.,Quon, Check Y.,Arvanitis, Argyrios

, p. 833 - 848 (2007/10/03)

The synthesis and CRF receptor binding affinities of several new series of N-aryltriazolo- and -imidazopyrimidines and -pyridines are described. These cyclized systems were prepared from appropriately substituted diaminopyrimidines or -pyridines by nitrous acid, orthoester, or acyl halide treatment. Variations of amino (ether) pendants and aromatic substituents have defined the structure-activity relationships of these series and resulted in the identification of a variety of high-affinity agents (K(i)'s 1 has been selected for further pharmacological studies that will be reported in due course.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 169882-27-3